[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Azienda Ospedaliero, Universitaria Pisana\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,65,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100502304","patients-with-severe-tricuspid-regurgitation-after-tricvalve-system-implantation-100502304",false,"NCT05820516","Patients With Severe TrIcuspid Regurgitation After triCvALve System Implantation","Cardiovascular, Renal and haemodynamIc Outcomes in Patients With Severe TrIcuspid Regurgitation After triCvALve System Implantation: an International Registry - CRITICAL INTERNATIONAL REGISTRY","CRITICAL","Inclusion Criteria\n\n1. The subject must be 18 years of age or older\n2. The subject must be a patient with massive or torrential symptomatic tricuspid regurgitation demonstrated by echocardiography with significant backflow in the IVC and\u002For SVC and with a v-wave ≥ 25 mmHg as demonstrated by right heart catheterization (measured in the IVC and\u002For SVC 2-4 cm above\u002F below right atrium (RA) inflow) within 8 weeks prior to the implantation\n3. Suitable for TricValve Transcatheter Bicaval Valves System implantation according to anatomic criteria by computed tomography (CT)inserire la parte retrospettiva ossia i pazienti che già hanno avuto l'impianto\n4. The subjects must have severe, tricuspid regurgitation leading to New York Heart Association (NYHA) class III or IV\n5. Distance covered in 6-minute walk test (6MWT) ≥ 60m\n6. Patient\u002Fauthorized legal guardian understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent Patient\u002Fpatient's authorized legal guardian is geographically stable (or willing to return for required study follow-up) and understands and is willing to fulfil all of the expected requirements of the clinical protocol\n\nExclusion Criteria\n\n1. Known significant intracardiac shunt (e.g. ventricular septal defect) or congenital structural heart disease based on heart team decision\n2. Requirement for other elective cardiac procedures e.g. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG) up to 90 days after the procedure or 30 days before the procedure\n3. Right ventricular failure (TAPSE ≤13 mm)\n4. Systolic pulmonary arterial pressure \\> 65 mmHg as assessed by Doppler echocardiography\n5. Life expectancy less than one year\n6. Cerebro-vascular event within the past 3 months\n7. History of mitral\u002Ftricuspid endocarditis within the last 12 months\n8. Patient has untreated significant left sided valvular heart disease which requires treatment (e.g. mitral regurgitation or stenosis, and aortic regurgitation or stenosis)\n9. Documented primary coagulopathy or platelet disorder, including thrombocytopenia (absolute platelet count \\\u003C90k)\n10. Documented evidence of significant renal dysfunction (serum creatinine \\> 3.0mg\u002Fdl) or on any form of dialysis at time of screening within the last 4 weeks\n11. Contraindication or known allergy to device's components, anti-coagulation therapy with vitamin K antagonists or contrast media that cannot be adequately pre-treated\n12. Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days)\n13. Currently participating in another study of an investigational drug or device that would directly impact the treatment or outcome of the current study","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","3 Years","OBSERVATIONAL","International Registry to collect patients with severe TR undergoing TricValve implantation from multiple Italian and European centers, aimed at:\n\n* Assessing the effect of TricValve implantation on cardiovascular and all-cause mortality, HF rehospitalization, renal function, functional capacity and quality of life.\n* Clarifying the haemodynamic effects of TricValve implantation and investigating their pathophysiological implications.",[26],"Severe Tricuspid Valve Regurgitation",[26,28],"TricValve","RECRUITING","2026-05-06",{"date":32,"type":33},"2026-05-11","ACTUAL",{"date":35,"type":33},"2025-02-01",{"date":37,"type":21},"2027-05",{"name":39,"class":40},"Azienda Ospedaliero, Universitaria Pisana","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100632343","study-in-patients-with-osteoporosis-and-fragility-fractures-to-estimate-the-extent-and-impact-of-delayed-administration-of-anti-fracture-therapy-100632343","NCT07512453","Study in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration of Anti-fracture Therapy","Retrospective Multicenter Study in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration of Anti-fracture Therapy","OPGAP01","Inclusion Criteria:\n\n* adult patients of both sexes;\n* patients with osteoporosis and\u002For previous fragility fractures (fragility fractures are defined as those that occur spontaneously, i.e., not resulting from trauma, even of low intensity, or those caused by a fall from standing height.\n* willingness to sign the consent form\n\nExclusion Criteria:\n\n* patients under the age of 18\n* no previous fragility fractures - failure to sign the consent form Exit criteria",{"count":51,"type":21},8000,"Osteoporosis (OP) and fragility fractures are a significant problem that leads to morbidity, mortality, and high costs for the National Health System. The treatment of fragility fractures includes numerous anti-resorptive and anabolic drugs, and its goal is the secondary prevention of new fractures. It is well known that the risk of a new fracture following a fracture event is highest in the months immediately following the first fracture. However, recent data clearly show a dramatic global delay in the administration of anti-osteoporotic therapy following a fragility fracture. It has been estimated that in Italy, 71% of patients with fragility fractures eligible for anti-fracture treatment did not receive timely treatment (a problem defined as a \"treatment gap\"), and that in 2034, the incidence of new fragility fractures will increase compared to 2019 \\[1\\]. However, there is a lack of real-life Italian data on the extent of the treatment gap in osteoporotic patients with fragility fractures and its impact in terms of the incidence of subsequent fragility fractures: this study therefore aims to fill this gap by collecting data from a large population of patients attending several centers throughout the country.",[54],"Osteoporosis",[56],"fractures and fragility","NOT_YET_RECRUITING","2026-04-01",{"date":60,"type":33},"2026-04-06",{"date":58,"type":21},{"date":63,"type":21},"2029-03-31",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100583486","nenca-study-on-neurological-complications-of-long-covid-19-in-children-and-adolescents-neurophysiological-electroencephalographic-and-neuroradiological-investigation-100583486","NCT06876948","NENCA Study on Neurological Complications of Long COVID-19 in Children and Adolescents; Neurophysiological, Electroencephalographic and Neuroradiological Investigation","STUDY of NEUROLOGICAL COMPLICATIONS of LONG COVID-19 in CHILDREN and ADOLESCENTS; NEUROPSYCHIATRIC, ELECTROENCEPHALOGRAPHIC and NEURORADIOLOGICAL INVESTIGATIONS","NENCA","Inclusion Criteria:\n\n* Age between 6 years and 16 years and 11 months\n* Symptomatology compatible with long neurological COVID, specifically: persistence or appearance of new neurological signs\u002Fsymptoms (e.g. fatigue, headache, sleep disturbance, cognitive dysfunction, memory difficulties, emotional or mood disorders, vertigo cognitive dysfunction, memory difficulties, emotional or mood disorders, dizziness, dysautonomia, movement disorders movement disorders, ataxia, tremor, epilepsy, muscle weakness, myalgia, hyposmia, hypogeusia hearing loss or tinnitus and\u002For sensorimotor deficits such as hypoesthesia, dysesthesia) after three months after established SARS-CoV-2 infection, as well as persistence of these symptoms for at least two months, in the absence of a clear aetiology.\n* Signature of the appropriate Informed Consent by caregiver(s) and patient(s)\n\nExclusion Criteria:\n\n* Poor knowledge of the Italian language or other limitation of verbal communication that compromises the subject's ability to perform neuropsychological tests\n* Need for sedation to perform brain MRI 7 Tesla\n* Neurological or neuropsychiatric disorder diagnosed prior to COVID-19 diagnosis\n* Caregiver's failure to sign consent","6 Years","16 Years",{"count":20,"type":21},"INTERVENTIONAL",[78],"NA","The study seeks to investigate the neurological effects caused by Covid-19 in children and adolescents in the 6-16 age group. To do this, neuropsychological scales, an EEG and an MRI were used.",[81],"Long Covid-19",[83],"Covid-19","2025-03-13",{"date":86,"type":33},"2025-03-14",{"date":88,"type":33},"2023-03-29",{"date":90,"type":21},"2026-04-28",{"name":39,"class":40},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":101,"studyType":23,"phases":4,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":41},"100563278","serum-calprotectin-in-surgical-septic-patients-100563278","NCT06614088","Serum Calprotectin in Surgical Septic Patients","Serum Calprotectin in Surgical Septic Patients as an Early Predictor of Clinical Severity and Mortality: a Prospective Comparative Study.","Inclusion Criteria:\n\n* diagnosis of upper\u002Flower gastro-intestinal perforation\n* diagnosis of intestinal occlusion\n* diagnosis of acute cholecystitis\n* diagnosis of complicated acute appendicitis\n* radiological diagnosis of intra-abdominal sepsis\n\nExclusion Criteria:\n\n* recent (\\\u003C3 months) surgery\n* recent (\\\u003C3 months) trauma\n* diagnosis of acute pancreatitis\n* diagnosis of burn",{"count":100,"type":21},150,"6 Months","To early evaluate the serum levels of calprotectin in patients suffering from intra-abdominal sepsis requiring a surgical treatment. The research project aims to investigate the role of serum calprotectin in the diagnosis of sepsis and to establish whether its level significantly correlates with different degree of disease severity and with short and long-term outcomes. If these associations were confirmed, serum calprotectin would represent an easily and rapidly detectable biomarker able to predict the severity of sepsis.",[104,105,106],"Infection, Intraabdominal","Sepsis Abdominal","Biomarker",[108,109],"Serum calprotectin","Surgical infections","2024-09-24",{"date":112,"type":33},"2024-09-26",{"date":114,"type":33},"2021-11-01",{"date":116,"type":21},"2025-01-01",{"name":39,"class":40},""]